LGND - LIGAND PHARMACEUTICALS INC

QQQ $ 446.25 $ -12.35 (-2.68 %)

DIA $ 404.28 $ -3.99 (-0.98 %)

SPY $ 539.90 $ -9.25 (-1.68 %)

TLT $ 99.49 $ -0.01 (-0.01 %)

GLD $ 230.65 $ -1.72 (-0.74 %)

Previous Close

$ 101.14

Open

Bid

$ 101.16 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 49.24 - $ 112.13

Volume

64,658

Average Volume

Market Cap

1.85B

Beta (5Y Monthly)

$ 1.12

PE Ratio (TTM)

$ 43.84

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-29-2024	12-31-2023	10-K
4	11-09-2023	09-30-2023	10-Q
5	08-09-2023	06-30-2023	10-Q
6	05-08-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-03-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	02-24-2021	12-31-2020	10-K
16	11-06-2020	09-30-2020	10-Q
17	08-07-2020	06-30-2020	10-Q
18	05-08-2020	03-31-2020	10-Q
19	02-27-2020	12-31-2019	10-K
20	11-08-2019	09-30-2019	10-Q
21	08-08-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	11-08-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q
27	03-01-2018	12-31-2017	10-K
28	11-09-2017	09-30-2017	10-Q
29	08-09-2017	06-30-2017	10-Q
30	05-09-2017	03-31-2017	10-Q
31	02-28-2017	12-31-2016	10-K
32	11-15-2016	09-30-2016	10-Q
33	08-04-2016	06-30-2016	10-Q
34	05-09-2016	03-31-2016	10-Q
35	02-26-2016	12-31-2015	10-K
36	11-09-2015	09-30-2015	10-Q
37	08-05-2015	06-30-2015	10-Q
38	05-11-2015	03-31-2015	10-Q
39	02-23-2015	12-31-2014	10-K
40	10-31-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Ligand Partner Travere Therapeutics Receiv...
09/06/2024 13:23:17

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; upda...

looking-into-ligand-pharmaceuticalss-recent-short-interest

Looking Into Ligand Pharmaceuticals's Rece...
08/16/2024 13:00:21

Benchmark Maintains Buy on Ligand Pharmace...
08/12/2024 16:53:08

Benchmark analyst Robert Wasserman maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target fro...

RBC Capital Reiterates Outperform on Ligan...
08/12/2024 16:28:30

RBC Capital analyst Douglas Miehm reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and maintains $130 price...

HC Wainwright & Co. Reiterates Buy on Liga...
08/08/2024 10:48:42

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...

RBC Capital Reiterates Outperform on Ligan...
08/07/2024 17:13:53

RBC Capital analyst Douglas Miehm reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and maintains $130 price...

Ligand Sees 2024 Core Adj. EPS $5.00-$5.50...
08/06/2024 20:49:38

Ligand Pharmaceuticals Q2 2024 Adj. EPS $1...
08/06/2024 20:27:38

Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate o...

Assessing Ligand Pharmaceuticals: Insights...
07/30/2024 12:01:10

RBC Capital Initiates Coverage On Ligand P...
07/30/2024 10:03:05

RBC Capital analyst Douglas Miehm initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and an...

Craig-Hallum Maintains Buy on Ligand Pharm...
07/09/2024 17:27:38

Craig-Hallum analyst Matt Hewitt maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from ...

HC Wainwright & Co. Reiterates Buy on Liga...
07/08/2024 17:58:16

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...

Ligand Pharma to Acquire APEIRON Biologics...
07/08/2024 11:08:27

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it has entered into a definitive agreement to acquire AP...

What 4 Analyst Ratings Have To Say About L...
06/28/2024 19:01:14

Benchmark Reiterates Buy on Ligand Pharmac...
06/28/2024 14:15:22

Benchmark analyst Robert Wasserman reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $95 price target.

HC Wainwright & Co. Reiterates Buy on Liga...
06/27/2024 15:46:31

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...

Ligand Pharmaceuticals Announces FDA Appro...
06/27/2024 12:04:10

FDA Approves CAPVAXIVE, Sixth Product Usin...
06/18/2024 12:03:40

HC Wainwright & Co. Reiterates Buy on Liga...
05/08/2024 10:33:15

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $1...

Ligand Pharmaceuticals Reaffirms FY24 Adj....
05/07/2024 21:23:45